Summary & Overview
HCPCS S0088: Imatinib, 100 mg
HCPCS Level II code S0088 designates Imatinib, 100 mg, a targeted oral chemotherapy agent commonly used in oncology. This code identifies the specific drug strength for billing and reimbursement across outpatient, infusion center, and pharmacy settings. Accurate coding for oral oncologic agents is critical for care continuity, patient access to therapy, and payer adjudication.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication outlines national benchmarks for billing and coverage patterns, highlights payer policy features relevant to oral oncology agents, and provides clinical context for use of Imatinib in cancer care.
Readers will learn: typical sites of service and coding context for S0088; how major commercial payers and Medicare approach coverage and claim processing for oral antineoplastic drugs; and common billing considerations that affect reimbursement and patient cost sharing. Data not available in the input is noted where applicable. The content is intended for a national audience of health system billing staff, oncology administrators, and policy analysts seeking concise guidance on HCPCS Level II code S0088.
Billing Code Overview
HCPCS Level II code S0088 represents Imatinib, 100 mg, an oral antineoplastic agent used in oncology for indications that include certain leukemias and gastrointestinal stromal tumors. The code denotes the specific drug formulation and strength for billing purposes.
Service Type: Oral chemotherapy drug administration / drug supply
Typical Site of Service: Outpatient clinic, infusion center for oncology drug billing, or pharmacy-dispensed oral oncology therapy
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult diagnosed with chronic myeloid leukemia (CML) or gastrointestinal stromal tumor (GIST) requiring oral targeted therapy with imatinib. The patient presents to an outpatient oncology clinic or specialty pharmacy for a prescription of S0088 (Imatinib, 100 mg) to be dispensed for ongoing disease control. Clinical workflow: the oncologist documents diagnosis, prior therapies, baseline labs (complete blood count, liver function tests), and potential drug interactions. The prescription is entered in the electronic medical record and transmitted to the infusion center–affiliated specialty pharmacy or outpatient pharmacy. The patient receives counseling on dosing, adverse effects, adherence, and monitoring schedule. Ongoing follow-up visits include assessment of response (hematologic and molecular testing for CML or imaging for GIST), toxicity management, and adjustments to dose or supportive care as needed. Typical site of service: outpatient oncology clinic, specialty pharmacy, or ambulatory infusion center pharmacy when medication is dispensed or administered under a pharmacy charge.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier | Standard reporting when no special circumstances apply |
22 | Increased procedural services | Rarely used for pharmacy drug code; may apply if unusually high work or resources were required for dispensing or documentation |
52 | Reduced services | If a portion of the expected pharmacy service was reduced or not provided |
53 | Discontinued procedure | When dispensing or service was initiated but discontinued prior to completion |
54 | Surgical care only | Not typically applicable to pharmacy-dispensed oral oncology agents |
55 | Postoperative management only | Not typically applicable |
56 | Preoperative management only | Not typically applicable |
62 | Two surgeons | Not applicable to this pharmacy drug code; rarely used in complex multidisciplinary billing |
78 | Unplanned return to the operating/procedure room by the same physician following initial procedure for a related procedure during the postoperative period | Not applicable |
80 | Assistant surgeon | Not applicable |
| Taxonomy Code | Specialty | Notes |
|---|---|---|
208000000X | Hematology/Oncology | Prescribers of S0088 for CML and related malignancies |
207Q00000X | Medical Oncology | Specialists managing systemic targeted therapy regimens |
1835S0201X | Oncology Pharmacy | Pharmacists providing specialty drug dispensing and counseling |
207RR0500X | Hematology | Hematologists managing CML monitoring and dose adjustments |
Related Diagnoses
| ICD-10 Code | Description | Clinical Relevance |
|---|---|---|
C92.1 | Chronic myelogenous leukemia [CML] | Primary hematologic indication for imatinib to achieve cytogenetic and molecular remission |
C49.A1 | Gastrointestinal stromal tumor of small intestine | GIST is a standard indication for imatinib for adjuvant therapy or metastatic disease |
C49.A2 | Gastrointestinal stromal tumor of rectum | Site-specific GIST diagnosis where imatinib may be indicated |
C80.1 | Malignant (primary) neoplasm, unspecified | Used when a malignancy requiring targeted therapy is documented but not yet fully classified |
D47.1 | Chronic myeloproliferative disease, unspecified | Diagnostic category that may encompass disorders treated with tyrosine kinase inhibitors in some scenarios |
Related CPT Codes
| CPT Code | Description | Relationship to This Procedure |
|---|---|---|
96372 | Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular | May be used if supportive injectable medications (e.g., antiemetics, growth factors) are administered in clinic alongside oral therapy management |
99213 | Office or other outpatient visit for the evaluation and management of an established patient, typically 15 minutes | Common outpatient follow-up visit where imatinib response and side effects are assessed and prescription renewed |
83520 | Drug assay, quantitative; immunoassay when performed in provider office/lab | May apply for therapeutic drug monitoring assays if performed as point-of-care or office-based testing |
88185 | Cytopathology, cell block; immunocytochemistry | Used for molecular or cytogenetic testing workflows that guide targeted therapy decisions |
81206 | BCR-ABL1 (e13a2 and e14a2) (eg, p210) (List separately in laboratory directories) | Molecular diagnostic code commonly used to monitor response in CML patients receiving imatinib |